**The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials**

Binghao Zhao, Wenxiong Zhang, Dongliang Yu, Jianjun Xu & Yiping Wei

Department of thoracic surgery, The second affiliated hospital of Nanchang University, Nanchang, China

**Abstract**

Nivolumab is a programmed cell death 1 (PD-1) receptor inhibitor antibody that enhances immune system antitumor activity. Although it is used for treating advanced non-small-cell lung cancer (NSCLC), its actual efficacy has not been determined. We searched PubMed, the Cochrane Library, Embase, MEDLINE, and Web of Science for related noncomparative clinical studies and randomized controlled trials (RCTs) to assess nivolumab benefit and risk in NSCLC. The main outcomes were objective response rate (ORR), 1-year overall survival rate (1-yOS rate), and progression-free survival rate at 24 weeks (PFS at 24 weeks rate), any-grade adverse effects rate (any-grade AEs%), and grade 3–4 AE rate (grade 3–4 AEs%). Relative risk (RR) was used to compare ORR in patients with positive and negative programmed cell death ligand 1 (PD-L1) expression. Random-effects models were used to determine pooled effect size and two-sided 95% confidence intervals (95% CI). We included 20 studies (17 noncomparative open-label cohort studies, three RCTs) involving 3404 patients in our meta-analysis. The modified nivolumab ORR was 18% (95% CI: 15–20%), the 1-yOS rate was 45% (95% CI: 40–50%), PFS at 24 weeks rate was 42% (95% CI: 37–48%), any-grade AEs% was 61% (95% CI: 50–73%), and grade 3–4 AEs% was 12% (95% CI: 9–16%). PD-L1 expression was related with the nivolumab ORR. Nivolumab potentially causes ongoing response, long-term PFS, and reduced treatment-related AEs. PD-L1 expression predicts the outcome of nivolumab immunotherapy. More high-quality and well-designed RCTs with large sample sizes are warranted to prove our findings.

**Introduction**

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 80–85% of all cases. Most patients with advanced NSCLC have poor prognosis, where the 5-year survival rate is <5% [1]. Checkpoints are specific molecules on T cells and antigen-presenting cells [2], when tumor cell activation of the signaling pathways downregulates the T-cell immune response. In this context, checkpoint inhibitors are new, emerging, potential strategies in oncology, especially in advanced NSCLC. Ipilimumab is a monoclonal inhibitor antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a known checkpoint, that has shown exciting effects on melanoma and lung cancer [3]. Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) may also demonstrate extensive antitumor activity [4, 5]. Nivolumab is a fully human immunoglobulin 4 (IgG4) PD-1 receptor inhibitor antibody that was approved in 2015 by the US Food and Drug Administration for treating melanoma, renal cell carcinoma, and NSCLC with durable response and tolerable toxicity. Besides, nivolumab reserves preferable option for classical Hodgkin’s lymphoma, head and neck squamous cell carcinoma (HNSCC), and urothelial cancer [6].
The pharmaceutical giant Bristol-Myers Squibb (BMS) provided the main sponsorship for producing this novel monoclonal antibody; however, many single-arm studies have reported the benefits and risks of nivolumab for treating NSCLC without control therapies, and the results reported were controversial. The small sample sizes were not adequately powered to detect the actual efficacy of nivolumab and might misestimate its performance in clinical practice. Hence, we systematically reviewed the current available literature to conduct the present single-arm meta-analysis with the aim of describing the general benefit and risk of nivolumab. The secondary objective was to evaluate whether the objective response rate (ORR) of nivolumab-treated patients with NSCLC with positive and negative PD-L1 expression is significantly different.

Materials and Methods
Our single-arm meta-analysis is accordance with PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) guidelines (Table S1) [7] and has been registered with PROSPERO (International Prospective Register of Systematic Reviews, CRD42017064411).

Search strategy
We systematically searched PubMed, the Cochrane Library, Embase, MEDLINE, and Web of Science from 1 January 2012 to 31 December 2017 without any language restrictions for noncomparative clinical studies and randomized controlled trials (RCTs). The combined text and medical subject heading (MeSH) terms used were as follows: “Carcinoma, Non-Small-Cell Lung” and “nivolumab.” The complete search we used for PubMed was as follows: (Carcinoma, Non-Small-Cell Lung [MeSH terms] OR Carcinoma, Non Small Cell Lung [text] OR Carcinomas, Non-Small-Cell Lung [text] OR Lung Carcinoma, Non-Small-Cell [text] OR Lung Carcinomas, Non-Small-Cell [text] OR Non-Small-Cell Lung Carcinomas [text]) AND (nivolumab [MeSH term] OR MDX-1106 [text] OR ONO-4538 [text] OR BMS-936558 [text] OR Opdivo [text]). We also manually searched the reference lists of the retrieved literature for further eligible articles.

Selection criteria
We included studies that met the following criteria [8]: (1) Adult patients with advanced NSCLC whose life expectancy was at least 3 months and without any autoimmune disease; Eastern Cooperative Oncology Group performance status was ≤2; there were no restrictions and no significant difference on sex, race, region, nationality, pretreatment; (2) Single-agent nivolumab or in combination with other chemotherapy drugs; (3) Whether comparison had been performed; (4) The main study outcome directly or indirectly included ORR, 1-year overall survival rate (1-yOS rate), progression-free survival rate at 24 weeks (PFS at 24 weeks rate), any-grade adverse effects rate (any-grade AEs%), and grade 3–4 adverse effects rate (grade 3–4 AEs%); treatment-related AE status was assessed using the Lung Cancer Symptom Scale and the European Quality of Life–5 Dimensions questionnaire [9]); and (5) Noncomparative clinical studies (noncomparative open-label studies) and RCTs.

The most complete and novel reports were included for data extraction and assessments if the objects were duplicated. We excluded reviews without original data, meta-analyses, and animal experiments.

Data extraction and quality assessment
Two investigators (W.X. Zhang and D.L. Yu) extracted the following information from each included study independently: first author, publication year, region, number of participants enrolled, participant characteristics, phase of clinical study, cohort completeness, tumor histology, clinical setting, endpoint, corresponding provided outcome, and study design. For noncomparative studies, we extracted total summarized data and subgroup figures or information if available; from the RCTs, we extracted data on clinical setting and outcome of intervention and control groups. The main outcomes were ORR, 1-yOS rate, PFS at 24 weeks rate, any-grade AEs%, and grade 3–4 AEs%.

The other outcomes included median OS (mOS, months), median PFS (mPFS, months), median duration of response (mDOR, weeks), complete response rate (CR), partial response rate (PR), stable disease rate (SD), disease control rate (DCR), and ongoing response rate. All extracted information and original data were entered in standardized tables. Although not treated as a main outcome, we report the detailed AE conditions and PD-L1 biomarker status. Disagreements were resolved by a third investigator (Y.P. Wei).

We used the Cochrane risk of bias tool [10] to evaluate the quality of eligible RCTs. However, there are no textbook quality guidelines for noncomparative clinical studies, for which there is large heterogeneity, to date [11]. Therefore, we only assessed study quality via powered data volume and integrity, distinguished journals, and influential writers or teams who represented the leading position of NSCLC course and research.

Statistical analysis
For the included studies, we analyzed the main outcomes only concerning nivolumab specifically. We input the total
clinical setting percentage for the main outcome and number of participants of each study, and then calculated the corresponding standard errors of these quasinormal distribution “rates” using Stata (StataCorp, USA). The 95% confidence lower interval (L1) and upper interval (U1) derived from the “rates” and standard errors could be justified. Lastly, the pooled effect sizes (ES), which denoted median “rates” and the 95% confidence intervals (95% CI), were output [12]. We also modified the final ES by omitting studies with large variability. Pooled ES aided the general evaluation of nivolumab benefit and risk. Heterogeneity across studies was examined by the Cochran Q chi-square test and the I² statistic. Studies with an I² statistic of 25–50%, 50–75%, and >75% were deemed to have low, moderate, and high heterogeneity, respectively [13]. P < 0.1 for the Q test was taken to indicate significant heterogeneity. We used random-effects models for all pooled ES because there was great subjectivity given the lack of related control groups in the noncomparative studies, and a tendency toward high heterogeneity [14]. Subgroup analyses were conducted according to study design, medication type, program subgroup, region, study phase, and histology. We performed subgroup analyses only for modified ORR and grade 3–4 AEs% because of the abundant available data.

Relative risk (RR) and the random-effects model were used to estimate whether there was a significant difference in ORR between patients with positive and negative PD-L1 expression.

Potential publication bias among the main outcomes was assessed using the Egger linear regression test [15].
All analyses were performed using Stata statistical software version 12.0 (StataCorp, USA, https://www.stata.com); two-sided $P < 0.05$ was considered statistically significant except where otherwise specified.

**Results**

**Study identification**

Searching the above-mentioned databases yielded a total 754 records, and we obtained another 30 records from the reference lists and Google Scholar. We excluded 61 articles for duplication, 648 studies were excluded for next exclusion. The sequence order step and quantity of next exclusion was (1) 588 studies were excluded for no corresponding studies ($n = 588$), (2) review ($n = 42$), (3) animal experiment ($n = 8$), and (4) meta-analysis ($n = 10$). The remaining 45 studies were assessed through full-text revision, and 25 of them were excluded because of two reasons: first no nivolumab exposure ($n = 12$) and second no available outcome data ($n = 13$). The remaining 20 articles were eligible for quantitative synthesis. Figure 1 shows the selection process.

**Study characteristics**

The present single-arm meta-analysis included a total 20 studies [16–35] involving 3404 participants; Table 1 describes the main study characteristics, and Table 2 presents the outcome results. The studies were all published between 2012 and 2017. The sample sizes of each study ranged from 33 to 582 (of a total 3404, there were 2754 patients in the nivolumab group for main outcome calculation). Three studies [23, 24, 35] were randomized, open-label studies (CheckMate 017, CheckMate 057; CheckMate 026, unblinded), and 17 studies [16–22, 33, 34] were noncomparative, open-label cohort studies. Nine studies [17–22, 26, 28, 30] were published abstracts, and eleven studies [16, 23–25, 27, 29, 31, 32, 35] were original studies. Three studies [29–31] had been performed in Europe; the remaining 17 [16–27, 31–35] had been conducted in North America. Eight studies [16–19, 21, 25, 32, 33] set nivolumab subgroups based on dosage or cycle; six studies [17–19, 21, 32, 33] used nivolumab concurrently with chemotherapy drugs (platinum-based [17, 32], ipilimumab [18, 19, 33], bevacizumab [21]). There were 10 phase I studies [16–19, 21, 22, 25, 26, 29, 31–33, 35], four phase II studies [20, 26, 27, 34], and six phase III studies [23, 24, 28–30, 35]. Five studies [20, 24, 27, 28, 30] included patients with squamous NSCLC for clinical study; two studies [23, 34] involved patients with nonsquamous NSCLC; and 13 studies [16–19, 21, 22, 25, 26, 29, 31–33, 35] involved mixed histological types. Eight studies reported the ORR in positive and negative PD-L1 expression. All studies were published in English, and all enrolled patients had received prior relevant therapy.

**Quality assessment**

The three RCTs [23, 24, 35] were assessed using the Cochrane risk of bias tool and did not demonstrate allocation concealment and blinding methods, but generated random sequences, provided complete outcome data, reported no selective outcome, and were free of other bias (Table S2). We included noncomparative studies from top journals or distinguished scientists, which ensured their high quality and integrity.

**Main outcome**

In 19 studies reporting ORR [16–28, 30–35], the pooled ORR was 20% (95% CI: 16–24%) with high heterogeneity ($I^2 = 87.3\%, P < 0.001$). After omitting six studies with large heterogeneity [21, 28, 32–35], the pooled ORR was 18% (95% CI: 15–20%) with low heterogeneity ($I^2 = 20.6\%, P = 0.235$; Table 3).

Ten studies reported the 1-yOS rate [21, 23–25, 27, 29, 31, 32, 34, 35]; the pooled 1-yOS rate was 55% (95% CI: 48–63%) with high heterogeneity ($I^2 = 83.6\%, P < 0.001$). After omitting five studies with great heterogeneity [21, 31, 32, 34, 35], the pooled 1-yOS rate was 45% (95% CI: 40–50%) with low heterogeneity ($I^2 = 20.6\%, P = 0.235$; Table 3).

Sixteen studies reported the PFS at 24 weeks rate [16, 18, 20, 31, 32, 35]; the pooled PFS at 24 weeks rate was 37% (95% CI: 30–45%) with moderate heterogeneity ($I^2 = 74.5\%, P = 0.004$). After omitting two studies with great heterogeneity [16, 20], the pooled result was 42% (95% CI: 37–48%) with quite low heterogeneity ($I^2 = 12.7\%, P = 0.329$; Table S3).

Fifteen studies reported the any-grade AEs% [19–25, 27, 29–35]; the pooled result was 60% (95% CI: 46–75%) with high heterogeneity ($I^2 = 96.4\%, P < 0.001$; Table S3). Fifteen studies reported the any-grade AEs% [19–25, 27, 29–35]; the pooled result was 60% (95% CI: 46–75%) with high heterogeneity ($I^2 = 96.4\%, P < 0.001$; Table S3).

Eighteen studies reported grade 3–4 AEs% [17–27, 29–35]; the pooled grade 3–4 AEs% was 20% (95% CI: 15–25%) with high heterogeneity ($I^2 = 93.4\%, P < 0.001$). After omitting five studies with extraordinary heterogeneity [17–19, 32, 33], the pooled result was 12% (95% CI: 9–16%) with little reduction in heterogeneity ($I^2 = 89.1\%, P < 0.001$; Table 6). Table S4 presents more details on the AEs%.
Table 1. Characteristics of clinical studies included in the single-arm meta-analysis.

| Study       | Region                  | Patients | Age (years) | Male (%) | Quit | Phase | Tumor histology | Drug          | Clinical setting | Combined with | Study design          |
|-------------|-------------------------|----------|-------------|----------|------|-------|-----------------|---------------|------------------|---------------|----------------------|
| 2012 Topalian et al. [16] | North America | 76       | NR          | NR       | NR   | I     | Squamous (n = 18) | Nivolumab 1 mg/kg (n = 18) | Q2W, IV total 12 cycles | NR           | Noncomparative open-label cohort study |
|             |                         |          |             |          |      |       | Nonsquamous (n = 56) | Nivolumab 3 mg/kg (n = 19) | Q2W, IV total 12 cycles |             |                      |
|             |                         |          |             |          |      |       | Unknown (n = 2)    | Nivolumab 10 mg/kg (n = 39) | Q2W, IV total 12 cycles |             |                      |
| 2013 Rizvi et al. [17] | North America | 43       | NR          | NR       | 3    | I     | Squamous (n = 15) | Nivolumab 10 mg/kg (n = 12)a | Q3W, IV          | Gemcitabine, cisplatin, pemetrexed, carboplatin, paclitaxel | Noncomparative open-label cohort study |
|             |                         |          |             |          |      |       | Nonsquamous (n = 28) | Nivolumab 10 mg/kg (n = 15)     | Q3W, IV          |             |                      |
|             |                         |          |             |          |      |       | Nivolumab 10 mg/kg (n = 16) | Q3W, IV          |                   |             |                      |
| 2014 Antonia et al. [18] | North America | 49       | NR          | NR       | 18   | I     | Squamous (n = 18) | Nivolumab 1 mg/kg (n = 24)    | Q3W, IV for 4 cycles followed by nivolumab 3 mg/kg, Q2W, IV | Ipilimumabd | Noncomparative open-label cohort study |
|             |                         |          |             |          |      |       | Nonsquamous (n = 31) | Nivolumab 3 mg/kg (n = 25)   | Q3W, IV for 4 cycles followed by nivolumab 3 mg/kg, Q2W, IV |             |                      |
| 2014 Ramalingam et al. [20] | North America | 117      | 65 (37–87)e | 73       | 11   | II    | Squamous (n = 117) | Nivolumab 3 mg/kg (n = 117) | Q2W, IV          | NR           | Noncomparative open-label cohort study |
| 2014 Rizvi et al. [21] | North America | 33       | NR          | NR       | NR   | I     | Squamous (n = 13) | Nivolumab 5 mg/kg (n = 12)     | Q3W, IV          | Bevacizumab (BEV) | Noncomparative open-label cohort study |
|             |                         |          |             |          |      |       | Nonsquamous (n = 20) | Nivolumab 3 mg/kg (n = 21)     | Q3W, IV          |             |                      |

(Continued)
| Study          | Region         | Patients | Age (years) | Male (%) | Quit | Phase | Tumor histology | Drug               | Clinical setting | Combined with | Study design            |
|----------------|----------------|----------|-------------|----------|------|-------|----------------|--------------------|------------------|---------------|------------------------|
| 2015 Bauer et al. [22] | North America | 226      | 67 (33–91)  | 55       | 47   | I     | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV         | NR           | Noncomparative open-label cohort study |
| 2015 Borghaei et al. [23] | North America | 292      | 61 (37–84)  | 52       | 15   | III   | Non-squamous    | Nivolumab 3 mg/kg  | Q2W, IV         | NR           | Randomised open-label study |
| 2015 Brahmer et al. [24] | North America | 135      | 62 (39–85)  | 82       | 4    | III   | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV         | NR           | Randomised open-label study |
| 2015 Gettinger et al. [25] | North America | 129      | 65 (38–85)  | 79       | 18   | I     | Squamous        | Nivolumab 1 mg/kg  | Q2W, IV for 12 cycles | NR          | Noncomparative open-label cohort study |
| 2015 Nishio et al. [26] | North America | 111      | NR          | NR       | NR   | II    | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV         | NR           | Noncomparative open-label cohort study |
| 2015 Rizvi et al. [27] | North America | 117      | 65 (57–61)  | 85       | 14   | II    | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV         | NR           | Noncomparative open-label cohort study |
| 2016 Bidoli et al. [28] | Europe        | 372      | NR          | NR       | NR   | III   | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV for 12 cycles | NR          | Noncomparative open-label cohort study |
| 2016 Crino et al. [30] | Europe        | 371      | NR          | 22       | NR   | III   | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV for 12 cycles | NR          | Noncomparative open-label cohort study |
| 2016 Gettinger et al. [31] | North America | 52       | 67 (43–85)  | 50       | 6    | I     | Squamous        | Nivolumab 3 mg/kg  | Q2W, IV         | NR           | Noncomparative open-label cohort study |

(Continued)
| Study       | Region          | Patients | Age (years) | Male (%) | Quit Phase | Tumor histology | Drug        | Clinical setting | Combined with                              | Study design            |
|------------|-----------------|----------|-------------|----------|------------|-----------------|-------------|-----------------|--------------------------------------------|-------------------------|
| 2016       | North America   | 56       | 64 (34–83)  | 46       | 12         | I               | Squamous     | Nivolumab       | Gemcitabine, cisplatin, pemetrexed, paclitaxel, carboplatin | Noncomparative open-label cohort study |
| 2016       | North America   | 76       | 64 (39–78)  | 65       | 12         | II              | Nonsquamous  | Nivolumab 3 mg/kg (n = 39) | Q2W, IV                   | Noncomparative open-label cohort study |
| 2016       | North America   | 270      | 63 (32–89)  | 68       | 27         | III             | Squamous     | Nivolumab 3 mg/kg (n = 270) | Q2W, IV for 6 cycles | Randomised open-label study               |
| 2017       | North America   | 77       | NR          | 10       | 10         | I               | Squamous     | Nivolumab (n = 38) | Q2W, IV                   | Noncomparative open-label cohort study |
| 2017       | North America   | 271      | 65 (29–87)  | 55       | 35         |                | Nonsquamous  | Nivolumab (n = 271) | Q3W, IV for 4 cycles | Noncomparative open-label cohort study |

Q2W, every 2 weeks; Q3W, every 3 weeks; IV, intravenous.

The same dosage and duration of nivolumab with different types of platinum-based doublet chemotherapy.

Complete response or progressive disease or unacceptable toxicity or achieved total medication cycles are all the endpoints.

Platinum-based doublet chemotherapy (gemcitabine, cisplatin, pemetrexed, carboplatin, and paclitaxel).

Ipilimumab is a recombinant, fully human, monoclonal antibody targeted at cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) that is available for the treatment of advanced melanoma.

Median age (range).

The same dosage and duration of nivolumab with different types of ipilimumab.
Table 2. Original data extracted from included studies.

| Study               | Patients | ORR (%) | 1-yOS rate % | Any-grade AEs % | Grade 3–4 AEs % | mOS months (Range) | mPFS months (Range) | mDOR weeks (Range) | CR % | PR % | SD % | DCR % | Ongoing response |
|---------------------|----------|---------|--------------|-----------------|-----------------|-------------------|--------------------|-------------------|------|------|------|------|-----------------|
| 2012 Topalian et al. [16] | Total (n=76) | 18.4 | NR | 26.3 | NR | NR | NR | NR | NR | (3.7–30.8)* | NR | NR | 6.6* | NR | NR |
| Arm A (n=18) | 5.6 | NR | 16.7 | NR | NR | NR | NR | NR | NR | 5.6 | NR | NR |
| Arm B (n=19) | 31.6 | NR | 42.1 | NR | NR | NR | NR | NR | NR | 32.7 | NR | NR |
| Arm C (n=39) | 17.9 | NR | 23.1 | NR | NR | NR | NR | NR | NR | 5.1 | NR | NR |
| 2013 Rizvi et al. [17] | Total (n=43) | 32.3 | NR | 48.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm A (n=12) | 33.0 | NR | 25.0 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm B (n=15) | 33.0 | NR | 46.7 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm C (n=16) | 31.0 | NR | 68.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| 2014 Antonia et al. [18] | Total (n=49) | 16.0 | NR | 49.0 | NR | NR | NR | NR | NR | NR | (6.1–49.1)* | NR | NR | NR |
| Arm A (n=24) | 12.5 | NR | 28.6 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm B (n=25) | 20.0 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| 2014 Antonia et al. [19] | Total (n=46) | 22.0 | NR | 84.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm A (n=22) | 13.6 | NR | 61.9 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm B (n=24) | 29.2 | NR | 39.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| 2014 Ramalingam et al. [20] | Total (n=117) | 12.0 | NR | 71.0 | 15.0 | NR | NR | NR | NR | NR | NR | NR | NR |
| 2014 Rizvi et al. [21] | Total (n=33) | 9.1 | NR | 72.7 | 25.0 | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm A (n=12) | 8.3 | NR | 91.7 | 25.0 | (33.3–86.7)* | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm B (n=21) | 9.5 | NR | 61.9 | 25.0 | (2.1–56.3) | NR | NR | NR | NR | NR | NR | NR | NR |
| 2015 Bauer et al. [22] | Total (n=226) | 15.8 | NR | 78.1 | 31.9 | NR | NR | NR | NR | NR | NR | NR | NR |
| Nivolumab (n=92) | 19.2 | NR | 68.2 | 10.3 | 12.2 | NR | NR | NR | NR | NR | NR | NR | NR |
| Docetaxel (n=95) | 12.4 | NR | 88.1 | 53.7 | 9.4 | (9.7–15.0)* | NR | NR | NR | NR | NR | NR |
| 2015 Brahmer et al. [24] | Total (n=272) | 14.3 | NR | 71.9 | 30.8 | NR | NR | NR | NR | NR | NR | NR | NR |
| Nivolumab (n=135) | 20.0 | NR | 58.0 | 6.9 | 9.2 | (7.3–13.3) | NR | NR | NR | NR | NR | NR |
| Docetaxel (n=137) | 8.8 | NR | 86.0 | 55.0 | 6.0 | (5.1–7.3) | NR | NR | NR | NR | NR | NR |
| 2015 Gettinger et al. [25] | Total (n=129) | 17.1 | NR | 41.1 | 14.0 | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm A (n=33) | 3.0 | NR | 33.3 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm B (n=37) | 24.3 | NR | 56.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Arm C (n=59) | 20.3 | NR | 37.3 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| 2015 Nishio et al. [26] | Total (n=111) | 21.6 | NR | 71.9 | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| 2015 Rizvi et al. [27] | Total (n=117) | 14.5 | NR | 74.4 | 17.1 | NR | NR | NR | NR | NR | NR | NR | NR |
| 2016 Bidoli et al. [28] | Total (n=372) | 4.0 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |

(Continued)
| Study        | Patients |
|--------------|----------|
|              | ORR (%)  | 1-yOS rate % | 24-week rate % | Any-grade AEs % | Grade 3–4 AEs % | mOS months (Range) | mPFS months (Range) | mDOR weeks (Range) | CR % | PR % | SD % | DCR % | Ongoing response % |
| Brustugun et al. [29] | Total (n = 58) | NR | 50.0 | NR | 31.0 | 5.2 | 11.7 | NR | NR | NR | NR | NR | NR |
| Crino et al. [30] | Total (n = 371) | 18.1 | NR | NR | 28.6 | 5.4 | 9.1 (6.7–11.5) | 3.6 | (4.2–25.8) | NR | 0.8 | 16.7 | 29.4 | 47.0 | NR |
| Gettinger et al. [31] | Total (n = 52) | 23.1 | 73.1 | 40.4 | 71.2 | 19.2 | 19.4 | (0.2–35.8) | (<0.1–28) | NR | NR | 26.9 | 50.0 | 66.7 |
| 2016 Rizvi et al. [32] | Total (n = 56) | 42.9 | 71.4 | 53.4 | 94.6 | 44.6 | NR | NR | NR | 1.8 | 41.1 | 42.9 | 85.7 | 41.7 |
| Arm A (n = 12) | 33.3 | 50.0 | 50.0 | NR | NR | 11.6 | (4.5–33.3) | 6.8 | (0.02–14.1) | NR | 5.7 | 10.3 (4.1–13.0) | 8.3 | 25.0 | 58.3 | 91.7 | 25.0 |
| Arm B (n = 15) | 46.7 | 86.7 | 73.3 | NR | NR | 19.2 | (7.6–35.1) | 4.8 | (0.9–24.6) | NR | 5.5 | (2.8–) | 0 | 46.7 | 46.7 | 93.3 | 28.6 |
| Arm C (n = 15) | 46.7 | 60.0 | 40.0 | NR | NR | 14.9 | (3.2–34.2) | 7.1 | (0.02–) | NR | 19.6 (5.1–) | 0 | 42.9 | 42.9 | 85.7 | 66.7 |
| Arm D (n = 14) | 42.9 | 85.7 | 50.0 | NR | NR | 14.9 | (8.8–30.1) | NR | NR | NR | NR | NR | NR |
| 2017 Hellmann et al. [33] | Total (n = 77) | 42.9 | NR | NR | 42.9 | 35.1 | NR | NR | NR | 8.1 (5.6–13.6) | (11.3–) | 0 | 47.4 | 31.6 | 78.9 | 72.2 |
| Arm A (n = 38) | 47.4 | NR | NR | 81.6 | 36.8 | NR | NR | NR | 3.9 (2.6–13.2) | (8.4–) | 0 | 38.5 | 17.9 | 56.4 | 80.0 |
| Arm B (n = 39) | 38.5 | NR | NR | 71.8 | 33.3 | NR | NR | NR | 2.8 (1.4–3.4) | (1.6–29.1) | 1.3 | 23.7 | 22.4 | NR | NR |
| 2016 Nishio et al. [34] | Total (n = 76) | 25.0 | 68.0 | NR | 84.2 | 22.4 | 17.1 | (13.3–23.0) | NR | NR | 0 | 42.9 | 24.7 | 67.5 | 75.6 |
| 2017 Carbone et al. [35] | Total (n = 541) | 26.0 | 56.0 | 40.0 | 71.0 | 18.0 | 14.4 | (11.7–19.4) | 4.2 (3.0–5.6) | 12.1 (1.7–19.4) | 2.0 | 24.0 | 38.0 | NR | NR |
| Nivolumab (n = 270) | 33.0 | 54.0 | 47.0 | 92.0 | 51.0 | 13.2 | (10.7–21.0) | 5.9 (5.4–6.9) | 5.7 (1.4–21.0) | 0 | 33.0 | 47.0 | NR | NR |
| Platinum chemo-therapy (n = 271) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |

ORR, Objective response rate; 1-yOS rate, 1-year overall survival rate; PFS at 24-week rate, progression-free survival rate at 24 weeks; any-grade AEs, any-grade treatment-related adverse effects; Grade 3–4 AEs, grade 3–4 treatment-related adverse effects; mOS, median overall survival; mPFS, median progression-free survival; mDOR, median duration of response; CR, complete response; PR, partial response; SD, stable disease; DCR, disease control rate; NR, no relevant statistic data.

aOnly range (one or two sides) available.
bOnly median available.
cMedian (range).
Other outcomes

In view of the limitations of clinical meaning and statistical methodology, we elected not to pool the other outcomes.

Subgroup analysis

To determine whether the treatment effect of nivolumab was consistent across various subgroups, the between-group treatment effect for the modified ORR and grade 3–4 AEs% was estimated within each category of the following classification variables: study design (RCT, noncomparative open-label cohort study), medication (nivolumab, nivolumab with other drugs), program subgroup (no subgroup therapy, with subgroup therapy), region (North America, Europe), study phase (I, II, III), and histology (squamous, nonsquamous, mixed). Table 7 lists the subgroup analysis results.

Table 3. Pooled objective response rate (ORR) and modified objective response rate (ORR) in non-small-cell lung cancer (NSCLC) patients for included studies.

| Study        | ORR (predeleted) | Study        | ORR (postdeleted) |
|--------------|------------------|--------------|-------------------|
|              | Median 95% CI    |              | Median 95% CI     |
| Total        | 20% 16–24%       | Total        | 18% 15–20%        |
| 2012 Topalian et al. | 18% 10–27%       | 2012 Topalian et al. | 18% 10–27%       |
| 2013 Rizvi et al. | 32% 18–46%       | 2013 Rizvi et al. | 32% 18–46%       |
| 2014 Antonia et al. | 16% 6–26%        | 2014 Antonia et al. | 16% 6–26%        |
| 2014 Antonia et al. | 22% 10–34%       | 2014 Antonia et al. | 22% 10–34%       |
| 2014 Ramalingam et al. | 12% 5–18%        | 2014 Ramalingam et al. | 12% 5–18%        |
| 2014 Rizvi et al. | 9% 0–19%         | 2015 Bauer et al. | 14% 9–18%        |
| 2015 Bauer et al. | 14% 9–18%        | 2015 Borghaei et al. | 19% 15–24%       |
| 2015 Borghaei et al. | 19% 15–24%       | 2015 Rizvi et al. | 14% 8–21%        |
| 2015 Brahmer et al. | 20% 13–27%       | 2015 Gettinger et al. | 17% 11–24%       |
| 2015 Gettinger et al. | 17% 11–24%       | 2015 Nishio et al. | 22% 14–29%       |
| 2015 Nishio et al. | 22% 14–29%       | 2015 Rizvi et al. | 14% 8–21%        |
| 2015 Rizvi et al. | 14% 8–21%        | 2016 Crino et al. | 18% 14–22%       |
| 2016 Biddo et al. | 4% 1–7%          | 2016 Gettinger et al. | 23% 12–35%       |
| 2016 Crino et al. | 18% 14–22%       | Overall ($I^2 = 20.6\%, P = 0.235$); Egger’s test ($P = 0.098$)
| 2016 Gettinger et al. | 23% 12–35%       | Overall ($I^2 = 87.3\%, P < 0.001$); Egger’s test ($P = 0.002$)
| 2017 Hellmann et al. | 43% 32–54%       |
| 2017 Nishio et al. | 25% 15–35%       |
| 2017 Carbone et al. | 26% 21–31%       |

Table 4. Pooled 1-year overall survival rate (1-yOS rate) and modified 1-year overall survival rate (1-yOS rate) in non-small-cell lung cancer (NSCLC) patients for included studies.

| Study        | 1-yOS rate (predeleted) | Study        | 1-yOS rate (postdeleted) |
|--------------|-------------------------|--------------|-------------------------|
|              | Median 95% CI           |              | Median 95% CI           |
| Total        | 55% 48–63%              | Total        | 45% 40–50%              |
| 2014 Rizvi et al. | 75% 51–99%              | 2015 Borghaei et al. | 51% 45–57%              |
| 2015 Borghaei et al. | 51% 45–57%              | 2015 Gettinger et al. | 42% 34–51%              |
| 2015 Rizvi et al. | 42% 33–50%              | 2015 Rizvi et al. | 39% 30–48%              |
| 2016 Brustugun et al. | 50% 37–63%              | 2016 Crino et al. | 50% 37–63%              |
| 2016 Gettinger et al. | 73% 61–85%              |
| 2016 Rizvi et al. | 71% 61–83%              |
| 2016 Nishio et al. | 68% 58–78%              |
| 2017 Carbone et al. | 56% 50–62%              |

Overall ($I^2 = 83.6\%, P < 0.001$); Egger’s test ($P = 0.257$)
ORR in PD-L1 expression

Eight studies [16, 18, 20, 23, 24, 27, 31, 34] reported the pending relationship between ORR and PD-L1 expression systematically. An expression level of <5% was deemed PD-L1-negative, and ≥5% expression was deemed PD-L1-positive. RR with the random-effects model was used because its assumptions accounted for the presence of

| Study            | ORR (predeleted) | Study            | ORR (postdeleted) |
|------------------|------------------|------------------|------------------|
|                 |                  |                  |                  |
|                 | Median 95% CI    |                 | Median 95% CI    |
|                 |                  |                  |                  |
| 2014 Rizvi et al. | 49% 34–64%       | 2014 Ramalingam et al. | 50% 34–64%       |
| 2014 Antonia et al. | 49% 35–63%       | 2014 Ramalingam et al. | 50% 34–64%       |
| 2014 Antonia et al. | 45% 31–59%       | 2015 Bauer et al.   | 2% 0–4%          |
| 2014 Ramalingam et al. | 15% 9–21%       | 2015 Borghaei et al. | 10% 7–14%        |
| 2014 Rizvi et al. | 25% 10–40%       | 2015 Bauer et al.   | 2% 0–4%          |
| 2014 Antonia et al. | 2% 0–4%         | 2015 Borghaei et al. | 10% 7–14%        |
| 2014 Rizvi et al. | 10% 7–14%        | 2015 Gettinger et al. | 14% 8–20%       |
| 2015 Bauer et al. | 14% 8–20%        | 2015 Nishio et al.  | 16% 9–23%        |
| 2015 Nishio et al. | 16% 9–23%        | 2016 Brustugun et al. | 17% 10–24%      |
| 2015 Rizvi et al. | 17% 10–24%       | 2016 Crino et al.   | 5% 3–8%          |
| 2016 Brustugun et al. | 5% 0–11%        | 2016 Gettinger et al. | 19% 8–30%       |
| 2016 Crino et al. | 5% 3–8%          | Overall (I^2 = 93.4%, P < 0.001); Egger’s test (P < 0.001)     |                  |
| 2016 Gettinger et al. | 19% 8–30%       |                  |                  |
| 2016 Rizvi et al. | 45% 32–58%       |                  |                  |
| 2017 Hellmann et al. | 35% 24–48%      |                  |                  |

 Overall (I^2 = 93.4%, P < 0.001); Egger’s test (P < 0.001)
variability among the studies. ORR had significant associations with PD-L1-positive and PD-L1-negative expression (95% CI: 1.71–3.38, P < 0.001) with no heterogeneity ($I^2 = 0$, $P = 0.541$; Fig. 2). Specifically, there was no significant association between PD-L1 expression with mixed histology (95% CI: 0.89–5.14, $P = 0.089$) and squamous NSCLC (95% CI: 0.97–2.87, $P = 0.066$) with no heterogeneity ($I^2 = 0$, $P = 0.369$; $I^2 = 0$, $P = 0.889$; Fig. 3).

### Publication bias diagnosis

The Egger regression test suggested bias in the ORR and grade 3–4 AEs% analysis and that the bias remained present in the grade 3–4 AEs% after studies of large variability had been removed. In fact, some deviations remained in the Egger test, as large heterogeneity across studies contributes to false positives in diagnosing publication bias [36]. Furthermore, most of the included clinical studies

---

**Table 7. Subgroup analysis of modified objective response rate (ORR) and grade 3–4 adverse effects rate (grade 3–4 AEs%) of nivolumab in non-small-cell lung cancer (NSCLC) patients.**

| Group                      | ORR            | Grade 3–4 AEs%        |
|---------------------------|----------------|-----------------------|
|                           | No. of studies | ES (95% CI)           | $P$ heterogeneity | $I^2$ (%) | No. of studies | ES (95% CI)           | $P$ heterogeneity | $I^2$ (%) |
| Total                     | 13             | 18% (15–20%)          | 0.235             | 20.6      | 13             | 12% (9–16%)           | <0.001             | 89.1     |
| Study design              |                |                       |                   |           |                |                       |                   |           |
| Randomized open-label study | 2             | 19% (16–23%)          | 0.374             | 0.0       | 3              | 12% (6–18%)           | 0.002             | 84.0     |
| Noncomparative open-label cohort study | 11          | 17% (15–20%)          | 0.192             | 26.4      | 10             | 13% (8–17%)           | <0.001             | 88.7     |
| Medication type           |                |                       |                   |           |                |                       |                   |           |
| Nivolumab                 | 10             | 17% (15–19%)          | 0.352             | 9.9       | 12             | 12% (8–16%)           | <0.001             | 89.4     |
| Nivolumab with other drugs$^a$ | 3             | 22% (13–31%)          | 0.183             | 41.4      | 1              | 25% (10–40%)          | NR                 | NR       |
| Program subgroup          |                |                       |                   |           |                |                       |                   |           |
| Subgroup therapy          | 5              | 19% (15–24%)          | 0.356             | 8.9       | 2              | 17% (7–27%)           | 0.176             | 45.3     |
| No subgroup therapy       | 8              | 17% (15–19%)          | 0.195             | 29.2      | 11             | 12% (8–16%)           | <0.001             | 89.8     |
| Region                    |                |                       |                   |           |                |                       |                   |           |
| North America             | 12             | 18% (15–20%)          | 0.185             | 26.4      | 11             | 14% (9–19%)           | <0.001             | 90.7     |
| Europe                    | 1              | 18% (14–22%)          | NR                | NR       | 2              | 5% (3–8%)             | 0.949             | 0.0      |
| Study phase               |                |                       |                   |           |                |                       |                   |           |
| I                         | 7              | 18% (14–22%)          | 0.199             | 30.1      | 4              | 14% (3–24%)           | <0.001             | 84.6     |
| II                        | 3              | 16% (10–21%)          | 0.145             | 48.3      | 4              | 17% (13–21%)          | 0.638             | 0.0      |
| III                       | 3              | 19% (16–22%)          | 0.872             | 0.0       | 5              | 9% (5–13%)            | <0.001             | 84.6     |
| Histology                 |                |                       |                   |           |                |                       |                   |           |
| Squamous                  | 4              | 16% (13–20%)          | 0.231             | 30.2      | 4              | 10% (5–16%)           | 0.001             | 81.3     |
| Nonsquamous               | 1              | 19% (15–24%)          | NR                | NR       | 2              | 16% (4–27%)           | 0.018             | 82.2     |
| Mixed histology$^c$       | 8              | 19% (15–22%)          | 0.203             | 28.3      | 7              | 13% (6–20%)           | <0.001             | 92.1     |

ES, Effect size (main outcome such as ORR or Grade 3–4 AEs% with corrected standard deviation); NR, no relevant statistic data.

$^a$Ipilimumab, bevacizumab, platinum-based doublet chemotherapy (gemcitabine, cisplatin, pemetrexed, carboplatin, paclitaxel).

$^b$The study contained different nivolumab therapy strategy of various dosage and duration et al.

$^c$Squamous, nonsquamous, adenocarcinoma, unknown types etc.
had been sponsored by BMS, and there is a distinct possibility that some reports associated with inverse positive results had been denied publication due to the desire for profit and pursuit of the sensational benefits of nivolumab. Next, ethical concerns and the particularity of patients hindered the measurement of some indicators; for example, for the 1-yOS rate, a precise experimental outcome could not be obtained from patients with short life expectancy, and patients with severe AEs in ongoing clinical studies might have discontinued treatment or died, hindering the extensive examination of grade 3–4 AEs%. Moreover, some of the included studies potentially described relevant data selectively (they might have obscured quite serious AEs), resulting in reports of outcome indicators that were not comprehensive and were incomplete. Partial withdrawal or loss of participants, obscured experiment outcomes, and unpublished studies accounted for publication bias.

**Summary**

This was a comprehensive single-arm meta-analysis of 17 noncomparative open-label cohort studies and three randomized open-label studies. The main outcome analysis of nivolumab in advanced NSCLC indicated a satisfactory, durable response with tolerable, manageable AEs. According to present synthesis data, PD-L1 expression highlighted the different efficacy of nivolumab in patients with different tumor microenvironment. Nivolumab can be regarded as potential antitumor drug and is worth popularization.

**Discussion**

From our manuscript we knew, nivolumab showed astonishing and persistent efficacy as well as manageable toxicity. The ORR was closely associated with PD-L1 expression in that positive PD-L1 expression resulted in a higher ORR. Most subgroups yielded results consistent with the overall outcome. There was pronounced ORR improvement in patients with nonsquamous NSCLC who had been treated with nivolumab plus ipilimumab; however, concurrent drug use might increase the potential risk of grade 3–4 AEs%.

Generally, the RCTs reported better results than the noncomparative studies, and phase III clinical studies reported more precise indications. However, considerable heterogeneity across studies limited the actual efficacy and possibility of first-line chemotherapy with nivolumab.

Our study is meaningful and has large impact on clinical practice especially in the patients with NSCLC immunotherapy treatment and management. Nivolumab has more beneficial response rate and overall survival than other second-line chemotherapy drugs (docetaxel), and less adverse effects (AEs) were detected in nivolumab group than in platinum-based group. All the efficacy and safety profile showed potential promotion of nivolumab. When comparing to other checkpoints (CTLA-4) inhibitor antibody, the final conclusion still keeps debatable and unclear; however, we found nivolumab plus ipilimumab improved the efficacy of single-agent nivolumab without significant AEs difference. Based on this finding, concurrent immunotherapy (such as nivolumab plus ipilimumab) might become standard strategy of crucial efficacy in oncology treatment. Furthermore, no evidence showed large exposure of nivolumab enhanced the overall survival of mixed histology patients with NSCLC, and treatment-related AEs kept no significant as well. So according to cost-effective analyses, nivolumab of 3 mg/kg Q2W is now the well-accepted administration methods. These meanings represent valuable priority for further studies and researches.

Inducing or potentiating immune responses via immunotherapeutic manipulation is a viable treatment approach in lung cancer. Currently, T-cell modulating agents are being investigated, where antibodies against CTLA-4, such as ipilimumab, exhibit great efficacy in treating NSCLC in combination with platinum-based chemotherapy [37]. PD-1 checkpoint blockade highlights the potential efficacy of the broad applicability of immunotherapy, and nivolumab, a BMS-sponsored human IgG4 monoclonal antibody, is the first approved immunotherapy drug for advanced squamous NSCLC [38]. Many reviews [6, 39–42] and clinical studies have summarized the good tolerance and favorable clinical activity of nivolumab against a wide variety of malignancies, including NSCLC. Nivolumab can block the activated phosphatidylinositol 3-kinase (PI3K)/AKT phosphatase SHP2 pathway that switches off T-cell and B-cell antitumor activity when PD-1 binds to PD-L1 [43, 44]. Some additional signaling pathway may also be involved in the inhibitor process. The encouraging efficacy can also be explained by the phenomenon that when PD-1 connects to PD-L1, coding somatic mutations create new epitopes or peptides identified by peripheral immune system to enhance antitumor immunity [45–49]. In the present meta-analysis, we found that patients with epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation received additional tyrosine kinase inhibitor therapy, as EGFR and ALK mutations derive great benefit from nivolumab [50]. The included studies involved various dosages and cycles of nivolumab, but the actual benefit and risk remain unknown; some reports have stated that high-dose nivolumab may confer obvious benefit but with uncontrolled AEs [51], but, on the contrary, some scientists insisted different nivolumab exposure was not associated with patients OS and toxicity [52]. The present meta-analysis shows that the most common AEs caused by nivolumab were fatigue and rash; there were few grade 3–4 AEs in the total AEs. We proved that PD-L1
expression predicted the efficacy of nivolumab treatment; in addition, high PD-L1 expression might inhibit tumor differentiation [53].

Although our main outcome analysis on nivolumab treatment is biologically plausible, the results of the included individual studies were dissimilar, as reflected in the significant heterogeneity. Although we selectively removed studies of great variability, heterogeneity remained for any-grade AEs% and grade 3–4 AEs%. We also performed subgroup analysis, and there was no significant heterogeneity change in grade 3–4 AEs%. Besides study design, the clinical study phase, region, and some unidentified elements also confounded our final outcome.

Differing participant characteristics may cause inconsistent results, and nonuniform, patient-level EGFR mutation or ALK translocation could also have led to potential heterogeneity. Not all patients that required ALK inhibitor and EGFR tyrosine kinase inhibitor therapy received it, and most of the studies did not report the details of the administration of the target drugs.

Differing medication administration strategies may also have contributed to the heterogeneity. For example, high-dose or long cycles of nivolumab may confer more benefit on patients with advanced NSCLC; the concurrent use of nivolumab with platinum-based drugs potentially increases grade 3–4 AEs%. There is no evidence that intravenous injection can help amplify nivolumab efficacy and reduce the AEs.

Methodologically, to a great extent, a single-arm meta-analysis is subject to subjectivity and heterogeneity. Furthermore, the measurement of outcome indicators differed greatly in the studies supported by BMS. Some negative results that would have affected the total efficacy of nivolumab might not have been reported. The lack of a standardized approach for assessing PD-L1 remained a limitation of the included studies.

Although there was inevitable heterogeneity in the included studies, our meta-analysis still has some strengths: We included more large-sample, high-quality studies, and our results are more convincing than those of Huang et al. [54], who reported a small meta-analysis that omitted studies on different nivolumab dosages (except 3 mg/kg) and concurrent drug use. We found nivolumab not only demonstrated encouraging ORR but also exhibited durable response rate, longer PFS. More powerful evidence enhanced the beneficial profile of nivolumab and expanded future potential efficacy. However, limited by a few heterogeneity, we still warranted more highly described RCTs. In addition, the present meta-analysis systematically reviewed the latest published studies, included subgroups of different aspects, and reported the general any-grade AEs%. Nivolumab has demonstrated extensive activity both as a single agent and in combination with other drugs, and further exploration is worthwhile. PD-L1 can be a potential biomarker for predicting prognosis in NSCLC, but the benefit of nivolumab is greatly limited in patients with negative PD-L1.

### Figure 2.

Forrest plots showing comparison of ORR between positive and negative PD-L1 expression in a random-effects model.
expression [55]. Does nivolumab still play a role in patients with advanced NSCLC with brain or bone metastasis? Whether we can find more surrogate checkpoint molecules expressed on resting or activation T cells, natural killers (NK) cells, etc., then reinforce these checkpoints as supplementary indicators for patients’ prognosis and emerging tactics to treat refractory malignants [56]? In addition, it will be important to establish the optimal timing of therapy and to determine whether immunotherapies are most effective when used alone or in combination with other agents. Promising results for immunotherapy have been reported, demonstrating CR and cures in patients with aggressive malignancies. The complex AEs and cost of engineering and administering some forms of immunotherapy limit the use to a distinct patient population. Accordingly, high-throughput and cost-effective techniques are being used to broaden the applications of immunotherapy for treating cancer [42, 57].

Our study still has some limitations. Initially, only two small studies reported results for nivolumab as compared with docetaxel; most of the included studies lacked control therapies. Due to the lack of terms of concrete control strategy, we only evaluated the efficacy and risk under subjectivity and selection bias without significantly statistical conclusions. Second, nonuniform patient level and trial level contributed to significant heterogeneity, and partial publication bias undermined the credibility of our results to an extent. However, most confounding factors were derived from methodology restrictions. Lastly, we could not extract sufficient details on the relationship between ORR and PD-L1 expression; more data are required to support the results of the 1-yOS rate and PFS at 24 weeks rate and to establish the assessments of other clinical endpoints such as the median OS, median PFS, CR, PR, and SD.

In summary, nivolumab has the potential to mount an ongoing, dynamic immune response for an extended period rather than a temporary killing of tumor cells after the pretarget therapy has been administered. The novel benefits and low risk of AEs enable nivolumab to emerge as a second-line chemotherapy drug, and with the use of other concurrent checkpoint antibodies, will form a

Figure 3. Forrest plots showing subgroup comparison of ORR between positive and negative PD-L1 expression in a random-effects model.
new approach to treating cancer. More high-quality and adequately powered RCTs are warranted to help interpret these conclusions with caution.

**Conflict of Interest**

The authors declare no potential conflict of interests.

**References**

1. Peters, S. Immunotherapy for lung cancer. Annals of Oncology Conference: 13th Annual Meeting of the Japanese Society of Medical Oncology Sapporo Japan Conference Start: 20150716 Conference End: 20150718 Conference Publication: (varpagings)2015. p. vii7.

2. Alatrash, G., H. Jakher, P. D. Stafford, and E. A. Mittendorf. 2013. Cancer immunotherapies, their safety and toxicity. Expert Opin. Drug Saf. 12:631–645.

3. Rijavec, E., C. Genova, G. Barletta, G. Burrafato, F. Biello, M. G. Dal Bello, et al. 2014. Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. Expert Opin. Biol. Ther. 14:1007–1017.

4. Fulchiero, E., and A. Jimeno. 2014. Nivolumab. Drugs Today 50:791–802.

5. Guigay, J., F. Peyrade, and E. Saada. The role of PD-L1/PD1 pathway in SCCHN. Radiotherapy and Oncology Conference: 5th ICHNO International Conference on Innovative Approaches in Head and Neck Oncology Nice France Conference Start: 20150212 Conference End: 20150214 Conference Publication: (varpagings)2015. p. 29–30.

6. Harrington, K. J., R. L. Ferris, G. Blumenschein Jr, A. D. Colevas, J. Fayette, L. Licitra, et al. 2017. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 18:1104–1115.

7. Stewart, L. A., M. Clarke, M. Rovers, R. D. Riley, M. Simmonds, G. Stewart, et al. 2015. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA 313:1657–1665.

8. Landis, J. R., and G. G. Koch. 1977. The measurement of observer agreement for categorical data. Biometrics 33:159–174.

9. Hollen, P. J., R. J. Gralla, M. G. Kris, and L. M. Potanovich. 1993. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur. J. Cancer 29:S51–S58.

10. Higgins, J. P., D. G. Altman, P. C. Gotzsche, P. Juni, D. Moher, A. D. Oxman, et al. 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928.

11. Wells, G. A., B. J. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos, et al. 2014. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl. Eng. Agric. 18:727–734.

12. Ali, S. A., R. M. J. Donahue, H. Qureshi, and S. H. Vermund. 2009. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int. J. Infect. Dis. 13:9–19.

13. Higgins, J. P., S. G. Thompson, J. J. Deeks, and D. G. Altman. 2003. Measuring inconsistency in meta-analyses. BMJ 327:557–560.

14. Spittal, M. J., J. Pirkis, and L. C. Gurrin. 2015. Meta-analysis of incidence rate data in the presence of zero events. BMC Med. Res. Methodol. 15:42.

15. Langhorne, P. 1998. Bias in meta-analysis detected by a simple, graphical test. Prospectively identified trials could be used for comparison with meta-analyses. BMJ 316:2443–2454.

16. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443–2454.

17. Rizvi, N. A., S. J. Antonia, L. Q. M. Chow, J. R. Brahmer, R. A. Juergens, H. Borghaei, et al. 2013. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J. Clin. Oncol. 31:8072.

18. Antonia, S. J., S. Gettinger, J. Goldman, L. Q. Chow, R. Juergens, H. Borghaei, et al. 2014. Safety and efficacy of first-line nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in Non-Small Cell Lung Cancer (NSCLC): metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90:S32–S33.

19. Antonia, S. J., S. N. Gettinger, L. Q. M. Chow, R. A. Juergens, H. Borghaei, Y. Shen, et al. 2014. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J. Clin. Oncol. 32:8023.

20. Ramalingam, S. S., J. Mazieres, D. Planchard, T. E. Stinchcombe, G. K. Dy, S. J. Antonia, et al. 2014. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90:1266–1267.

21. Rizvi, N. A., S. J. Antonia, F. A. Shepherd, L. Q. Chow, J. Goldman, Y. Shen, et al. 2014. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC)
previously treated with chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 90:532.
22. Bauer, T. M., M. McCleod, J. C. Chandler, G. R. Blumenschein, L. S. Schwartzberg, H. Burris, et al. 2015. An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. J. Clin. Oncol. 33(15_suppl):3013.
23. Borghaei, H., L. Paz-Ares, L. Horn, D. R. Spigel, M. Steins, N. E. Ready, et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:1627–1639.
24. Brahmer, J., K. L. Reckamp, P. Baas, L. Crinò, W. E. Eberhardt, E. Poddubskaya, et al. 2015. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:123–135.
25. Gettinger, S. N., L. Horn, L. Gandhi, D. R. Spigel, S. J. Antonia, N. A. Rizvi, et al. 2015. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33:2004–2012.
26. Nishio, M., T. Hida, K. Nakagawa, H. Sakai, N. Nogami, S. Atagi, et al. 2015. Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(15_suppl):8027.
27. Rizvi, N. A., J. Mazieres, D. Planchard, T. E. Stinchcombe, G. K. Dy, S. J. Antonia, et al. 2015. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16:257–265.
28. Bidoli, P., R. Chiari, A. Catino, F. Grossi, C. Nobersasco, F. Gelsomino, et al. 2016. Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. Ann. Oncol. 27:1228P.
29. Brustugun, O. T., M. Sprauten, and Å. Helland. 2017. Real-world data on nivolumab treatment of non-small cell lung cancer. Acta Oncol. 56:438–440.
30. Crino, L., P. Bidoli, A. Delmonte, F. Grossi, F. De Marinis, F. Sperandi, et al. 2016. Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population. J. Clin. Oncol. 34:3067.
31. Gettinger, S., N. A. Rizvi, L. Q. Chow, H. Borghaei, J. Brahmer, N. Ready, et al. 2016. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 34:2980–2987.
32. Rizvi, N. A., M. D. Hellmann, J. R. Brahmer, R. A. Juergens, H. Borghaei, S. Gettinger, et al. 2016. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 34:2969–2979.
33. Hellmann, M. D., N. A. Rizvi, J. W. Goldman, S. N. Gettinger, H. Borghaei, J. R. Brahmer, et al. 2017. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase I, multicohort study. Lancet Oncol. 18:31–41.
34. Nishio, M., T. Hida, S. Atagi, H. Sakai, K. Nakagawa, T. Takahashi, et al. 2016. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open 1:e000108.
35. Carbone, D. P., M. Reck, L. Paz-Ares, B. Creelan, L. Horn, M. Steins, et al. 2017. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376:2415–2426.
36. Sterne, J., M. Egger, G. Smith, A. C. Jonathan, M. E. Sterne, and G. D. Smith. 2001. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323:101–105.
37. Reck, M. 2012. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann. Oncol. 23:viii28–viii34.
38. Lim, J. S. J., and R. A. Soo. 2016. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. Ther. Adv. Respir. Dis. 10:444–454.
39. Quoix, E., and J. M. Limacher. 2014. Immunotherapy for non-small-cell lung cancer: current approaches. Curr. Respir. Care Rep. 3:19–25.
40. La-Beck, N. M., G. W. Jean, C. Huynh, S. K. Alzghari, and D. B. Lowe. 2015. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 35:963–976.
41. Wendling, P. 2015. Nivolumab transforms practice for advanced, refractory nonsquamous NSCLC. Oncol. Rep. 11:22–23.
42. Rajan, A., C. Kim, C. R. Heery, U. Guha, and J. L. Gulley. 2016. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers. Hum. Vaccin. Immunother. 12:2219–2231.
43. Wolchok, J. D. 2015. PD-1 Blockers. Cell 162:937.
44. Zimmerman, M. P., and S. R. Mehr. 2014. Targeted programmed cell death in lung cancer treatment. Am. J. Manag. Care. 20:SP155–SP157.
45. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252–264.
46. Khunger, M., A. V. Hernandez, V. Pasupuleti, S. Rakshit, N. A. Pennell, J. Stevenson, et al. 2017. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis. JCO Precis. Oncol. 2017(1):1–15.
47. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793.
48. Blank, C., I. Brown, A. C. Peterson, M. Spiotto, Y. Iwai, T. Honjo, et al. 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64:1140–1145.
49. Taube, J. M., R. A. Anders, G. D. Young, H. Xu, R. Sharma, T. L. Mcmiller, et al. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4:127ra37.
50. Abdel-Rahman, O. M. 2016. Personalized PD-1/PD-L1 inhibitor therapy for advanced non small cell lung cancer beyond first line; a meta-analysis of potential predictive factors. Ann. Oncol. 27:1089P.
51. Jones, E., C. Mikropoulos, and M. Ahmed. 2015. The future of immunotherapy in the treatment of lung cancer. Lung Cancer Manag. 4:57–73.
52. Feng, Y., X. Wang, G. Bajaj, S. Agrawal, A. Bello, B. Lestini, et al. 2017. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin. Cancer Res. 23:5394.
53. Pan, Z. K., F. Ye, X. Wu, H. X. An, and J. X. Wu. 2015. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J. Thorac. Dis. 7:462.
54. Huang, J., Y. Zhang, J. Sheng, H. Zhang, W. Fang, J. Zhan, et al. 2016. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. Onco Targets Ther. 9:5867–5874.
55. Grigg, C., and N. A. Rizvi. 2016. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J. Immunother. Cancer 4:48.
56. 2017. Opdivo (nivolumab) prescribing information. Bristol-Myers Squibb, Princeton, NJ.
57. De, V. G., Y. Je, D. Bossé, M. M. Awad, P. A. Ott, R. B. Moreira, et al. 2017. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol. Res. 5:312–318.

Supporting Information

Additional supporting information may be found in the online version of this article:
Table S1. PRISMA checklist.
Table S2. Risk of bias assessments for two randomized studies.
Table S3. PFS at 24 weeks rate.
Table S4. Detailed treatment-related adverse effects of nivolumab in non-small cell lung cancer (NSCLC) patients.